Results 61 to 70 of about 19,548 (244)

Challenging the Clostridium botulinum toxin type A (BoNT/A) with a selection of microorganisms by culture methods and extended storage of used vials to assess the loss of sterility [PDF]

, 2015
In 2002, botulinum toxin type A (BoNT/A) was approved by the US Food and Drug Administration (FDA) for cosmetic use. However, there may be procedural differences between the ways in which a clinician handles, applies and stores the product compared to ...
Crean, Stjohn, Dennison, Sarah Rachel, Morton, Leslie Hugh Glyn, Singhrao, Simarjit Kaur, Turner, Martin   +4 more
core  

Wound botulism in injectors of drugs: upsurge in cases in England during 2004. [PDF]

, 2005
Wound infections due to Clostridium botulinum were not recognised in the UK and Republic of Ireland before 2000. C. botulinum produces a potent neurotoxin which can cause paralysis and death. In 2000 and 2001, ten cases were clinically recognised, with a
Akbulut, D, de Souza-Thomas, L, Dennis, J, Gent, M, Grant, KA, Hope, V, McLauchlin, J, Mithani, V, Mpamugo, O, Ncube, F, Ohai, C   +10 more
core   +1 more source

Botulinum neurotoxin: Not only in Dermatology - Expanding Therapeutic Horizons Across Medical Specialties

Journal of Education, Health and Sport
Background. Botulinum neurotoxin (BTX) is commonly associated with cosmetic applications; however, its therapeutic relevance extends far beyond aesthetic medicine.
Klaudia Kurzątkowska, Dominika Marszałek, Aleksandra Ocimek, Michalina Czudowska, Magdalena Zawadzka, Emilia Borychowska, Karolina Gwóźdź, Zofia Aneta Mierzejewska, Marta Drozdowska, Aleksandra Natalia Bytros   +9 more
doaj   +1 more source

Single Application of A2 NTX, a Botulinum Toxin A2 Subunit, Prevents Chronic Pain Over Long Periods in Both Diabetic and Spinal Cord Injury–Induced Neuropathic Pain Models

Journal of Pharmacological Sciences, 2012
Botulinum toxin type A is a unique candidate for inhibition of pain transmission. In the present study we attempted to see the beneficial actions of A2 neurotoxin (NTX), an active subunit of botulinum toxin type A.
Lin Ma, Jun Nagai, Yuki Sekino, Yoshitaka Goto, Shinji Nakahira, Hiroshi Ueda   +5 more
doaj   +1 more source

A Cell Line for Detection of Botulinum Neurotoxin Type B [PDF]

, 2017
Botulinum neurotoxins (BoNTs) type A and type B are commonly used as biopharmaceutics for neurological diseases, uniquely allowing months-long paralysis of target muscles.
Adler, Antonucci, Arsenault, Bak, Binz, Binz, Boute, Chaddock, Davletov, Erbguth, Fernández-Salas, Ferreira, Foran, Foran, Foster, Gordon, Koriazova, Lacy, Lacy, Marini, Montecucco, Montecucco, Pirazzini, Puhar, Rossetto, Rummel, Rust, Schiavo, Sesardic, Strotmeier, Swift, Whitemarsh, Wictome, Wild, Yowler, Yu   +35 more
core   +2 more sources

Orofacial Drinking Tremor: A Case Series and Literature Review

Movement Disorders Clinical Practice, EarlyView.
Abstract Background Task‐specific orofacial tremor is a rare condition in which rhythmic oscillations of orofacial muscles occur during specific actions. Drinking tremor represents a recurrent pattern in isolated reports, although its phenomenology and underlying mechanisms remain incompletely defined.
Daniele Birreci, Luca Angelini, Simone Aloisio, Anna S. Grandolfo, Sara Cirinei, Adriana Martini, Martina De Riggi, Matteo Bologna   +7 more
wiley   +1 more source

Histopathological changes of the buccal mucosa and skin after botulinum neurotoxin intramuscular injection in rats (immunohistochemical study)

BMC Oral Health
Background A surplus of clinical studies focused mainly on the clinical impacts of botulinum neurotoxin type A disregarding the histopathological changes stemming from its injection.
Gihan S. Hassan, Basant H. Abouzaid, Reda G. Saleh   +2 more
doaj   +1 more source

Capsaicin protects neuromuscular junctions from the inhibitory effects of botulinum neurotoxin A [PDF]

, 2008
Within 24 hrs after injecting botulinum neurotoxin A (BoNT/A) into the hindlimb, mice lost the toe spread reflex and developed progressive muscle weakness. At the same time, the compound muscle action potential amplitude decreased. Injection of capsaicin
Baskaran Thyagarajan, Carmen Garcia, Joseph McArdle, Joseph Potian, Kormakur Hognason, Natalia Krivitskaya   +5 more
core   +1 more source

Genomic and physiological variability within Group II (non-proteolytic) Clostridium botulinum [PDF]

, 2013
BACKGROUND: Clostridium botulinum is a group of four physiologically and phylogenetically distinct bacteria that produce botulinum neurotoxin. While studies have characterised variability between strains of Group I (proteolytic) C. botulinum, the genetic
Andrew T Carter, Ewelina Wachnicka, Lisa C Crossman, Martin D Webb, Michael W Peck, Mohammed Sebaihia, Sandra C Stringer   +6 more
core   +1 more source

Synaptotagmin Binding to Botulinum Neurotoxins

Biochemistry, 2019
Botulinum neurotoxins (BoNTs) are exceptionally toxic proteins that cause paralysis but are also extensively used as treatment for various medical conditions. Most BoNTs bind two receptors on neuronal cells, namely, a ganglioside and a protein receptor.
Markel Martínez-Carranza, Pilar Blasco, Robert Gustafsson, Min Dong, Ronnie Per-Arne Berntsson, Göran Widmalm, Pål Stenmark   +6 more
openaire   +4 more sources